Chandramouli Nagarajan

机构：SingHealth, Singapore General Hospital, National Cancer Centre Singapore

发表论文 11 篇 · 总被引 152 次 · h-index 3

代表论文

• International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma (2024 · The Lancet Oncology · 被引 129)
• Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis. (2024 · Journal of Clinical Oncology · 被引 12)
• A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia (2024 · Heliyon · 被引 9)
• Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis (2025 · Blood · 被引 1)
• Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1 (2025 · Blood · 被引 1)
• Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings (2025 · Blood)